SOURCE: Scandinavian Clinical Nutrition

August 29, 2007 11:25 ET

Scandinavian Clinical Nutrition Inks 11 International Export Agreements

Acquisition Leads to International Launches of Coldizin and Immulina

STOCKHOLM, SWEDEN--(Marketwire - August 29, 2007) - Scandinavian Clinical Nutrition AB (SCN MTF) has signed 11 new export agreements for patent-protected and trademarked products Coldizin, made to support immunity against common colds, and Immulin, which stimulates the immune system. Both products were transferred to SCN during the July/August 2007 acquisition of the Danish biotech company Nordic Phytopharma (NPP) for $8.9 million.

Ten markets are scheduled for a Fall 2007 launch date, with additional launches anticipated throughout the year. Coldizin is currently sold in Norway, Sweden, Austria and Turkey, while Immulina has distribution in Denmark and Finland. In May 2007, SCN strengthened the company's position within the common cold category through a 20-year agreement with the Norwegian biotech company Life Capitol. The agreement gives SCN worldwide exclusivity to a patent-pending treatment for common colds and virus-related obesity.

"These export agreements have proven the value of the NPP acquisition and confirm the strategy that further validates our decision to select NPP as the exports department for all of SCN's products. These agreements will have an immediate effect on the company's profitability and future success, and we are anticipating to sign additional agreements by the end of the year," says Ulf Söderberg, CEO of SCN.

Research has shown that the patented product Coldizin reduces symptoms of common colds in the respiratory system within 24 hours. Two international patents protect the unique composition and effects of this product. Immulina is a patented product that strengthens the immune defense system, with a particular effect on the macrophages. Immulina was developed by researchers at the University of Mississippi, and SCN has licensed the patents for the duration time they will remain in effect -- roughly twenty years.

In addition, Coldizin agreements have been signed with partners in Indonesia, Denmark, Finland, Portugal, Poland, Great Britain and Ireland. Agreements for Immulina have been signed for the markets in Sweden, Norway, Poland and France. The agreements have a contractual period of three to five years.

In a brief period of time, the acquisition of NPP has provided SCN with access to several products that will bring significant value to their investment in sales and marketing subsidiaries in selected markets, such as the USA. NPP's wealth of international sales experience is expected to strengthen SCN's position in the world market, and will begin functioning as the exports department for all of SCN's products throughout the Q4 2007.

SCN maintains its R & D focus though their research agreement with the Swedish Karolinska Institute, one of the world's most respected medical universities, and the institution that awards the Nobel Laureate in Physiology and Medicine. Through the recent acquisition of NPP, SCN has expanded their American research contacts at the University of Mississippi. Now SCN also has access to leading professors at the Johns Hopkins University in Baltimore, as well as the Danish Panum Institute at the University of Copenhagen.

About Scandinavian Clinical Nutrition

Scandinavian Clinical Nutrition AB (SCN MTF) acts as a holding company and marketing arm in the development and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as CUUR, Membraseven, and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create the ideal conditions for profitable growth both in Sweden and internationally. The SCN share is listed for trade on NGM Nordic MTF since December 6, 2006. For more information, please visit

Contact Information

  • Press Contact:
    Lindsey Carnett
    Marketing Director
    Email Contact
    +1 (805) 405-3966

    Investor Relations:
    Ulf Söderberg
    Email Contact
    +46 708 13 22 81
    +46 761 058 099